BioStem Technologies, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jason Matuszewski
- Full Time Employees
- 73
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4901 Northwest 17th Way Fort Lauderdale FL United States of America 33309
- IPO Date
- Mar 17, 2015
- CIK
- 0001658678
- Website
- biostemtechnologies.com
- Similar Companies
- Business
- BioStem Technologies, Inc. (OTC: BSEM) BioStem Technologies, Inc. is a regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies. The company produces innovative perinatal tissue-based products using its proprietary BioREtain processing method, which preserves the tissue's natural growth factors, cytokines, extracellular matrix, and structural integrity while adhering to AATB-accredited, FDA-registered, and cGMP-compliant standards; its core portfolio includes membrane allografts such as VENDAJE, VENDAJE AC, VENDAJE OPTIC, AmnioWrap2, American Amnion, and American AC, designed as protective coverings for soft tissue wounds including diabetic foot ulcers, venous stasis ulcers, and surgical applications, with additional offerings in biologic stem cell alternatives for joint pain, tendon and ligament injuries, neurodegenerative and autoimmune diseases, as well as nutraceuticals under the Dr. Dave’s Best and Nesvik Organics brands sold via e-commerce. Founded in 2014 and headquartered in Pompano Beach, Florida, BioStem Technologies operates primarily in the United States with international nutraceutical distribution and targets clinicians, hospitals, and patients in wound care and orthopedics. In recent developments, the company signed a letter of intent in November 2024 to acquire FDA 510(k)-cleared wound care products ProgenaMatrix—a human keratin matrix—and revyve Antimicrobial Wound Gel from ProgenaCare Global to expand its hospital-based portfolio and treatment continuum; it purchased a four-acre land parcel in Boca Raton's Research Park at Florida Atlantic University in November 2025 for a new $49.5 million headquarters, manufacturing, and distribution facility, planning to create 100 high-paying jobs; and expanded product access in Medicaid markets while reporting third-quarter 2025 financial results and restating prior statements for 2023 through mid-2025.
Company News
BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier
BioStem Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference
BioStem Technologies Eyes Surgical Growth, Manufacturing Shift After BioTissue Deal
Comparing BioStem Technologies (OTCMKTS:BSEM) and Enlivex Therapeutics (NASDAQ:ENLV)
BioStem Technologies to Present at the Sidoti MicroCap Conference
BioStem Technologies Q2 Earnings Call Highlights
BioStem Technologies, Inc. (BSEM) Q2 2026 Earnings Call Transcript
BioStem Technologies, Inc. (BSEM) Reports Q2 Loss, Beats Revenue Estimates
BioStem Technologies Reports Second Quarter 2026 Financial Results
BioStem Technologies Announces Nasdaq Uplisting
BioStem Technologies to Host Second Quarter 2026 Financial Results Conference Call on August 12, 2026
BioStem Technologies Publicly Files Form 10 Registration Statement with the Securities and Exchange Commission
BioStem Technologies Announces Issuance of Four U.S. Design Patents Covering Fenestrated Human Placental Allograft Technologies
BioStem Technologies to Present at the Planet MicroCap Las Vegas 2026 Conference
BioStem Technologies Announces Appointment of Three New Members to its Board of Directors
BioStem Technologies Announces $2.5 Million Private Placement Financing with its First Institutional Investor
BioStem Technologies Q1 Earnings Call Highlights
BioStem Technologies, Inc. (BSEM) Q1 2026 Earnings Call Transcript
BioStem Technologies, Inc. (BSEM) Reports Q1 Loss, Tops Revenue Estimates
BioStem Technologies Reports First Quarter 2026 Financial Results